Biothera Acquires MUC1 Anti-Cancer Monoclonal Antibody From Antisoma

EAGAN, Minn.--(BUSINESS WIRE)-- Biothera announced today that it has acquired the anti-cancer monoclonal antibody AS1402 from Antisoma for undisclosed terms.

AS1402 is a monoclonal antibody that targets an aberrant form of the cell-surface protein MUC1 that is widely expressed in many types of cancer. Prior to the acquisition, the experimental drug had been in Phase 2 development.

Biothera’s Imprime PGG® is a novel immunotherapy that works synergistically with anti-tumor monoclonal antibodies. Imprime PGG activates the largest population of the body’s immune cells (neutrophils), enabling them to recognize and kill antibody-targeted cancer cells.

Biothera plans to study the combination therapy of Imprime PGG and AS1402 in future cancer trials. The indication(s) has (have) yet to be determined.

“We believe the combination of Imprime PGG and AS1402 could create a potent therapy to treat a wide range of cancers,” said Dan Conners, President, Biothera Pharmaceutical Group.

“This deal gives Biothera the opportunity to pursue an interesting new approach with AS1402 while at the same time realising value for Antisoma,” said Nicholas Adams, Vice President of Business Development at Antisoma.

About Biothera, the Immune Health Company

Biothera is a privately held biotechnology company dedicated to improving immune health. The company is developing pharmaceuticals that engage the innate immune system to fight cancer. Its lead cancer drug Imprime PGG is currently in multiple Phase 2 clinical trials for non-small cell lung and in a Phase 3 for colorectal cancer. (

About Antisoma

Antisoma is a London Stock Exchange-listed biopharmaceutical company that develops novel products for the treatment of cancer. The Company has operations in the UK and the US. Please visit for further information about Antisoma.


Biothera, the Immune Health Company
David Walsh, +1-651-256-4606 (direct)
VP Communications
[email protected]

KEYWORDS:   United States  North America  Minnesota

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology  Pharmaceutical  Radiology



Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.